Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
Completed · Phase 3 · NCT02814916
Conditions: Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
At a glance
- Research payments reported, 2025
- $2,600
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 199
About the trial
- Sponsor
- AbbVie
- Tested
- Dalbavancin (drug), Vancomycin (drug), Oxacillin (drug), Flucloxacillin (drug), Cefadroxil (drug), Clindamycin (drug)
- Dates
- Started 2017-03-30; completion 2024-01-01
- Results posted
- Yes
To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.
From ClinicalTrials.gov, last updated 2024-09-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $2,600 in research payments for this study in 2025 (1 payments).
Products named: Dalvance
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.